SCHEMBL2296005

SCHEMBL2296005

CC(C)(N)CNc1ncccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.50
FDPS P14324 1/20 0.47
HPGD P15428 1/20 0.36
SLC6A2 P23975 1/20 0.35
TAAR1 Q96RJ0 1/20 0.35
SYK P43405 1/20 0.35
PRKCH P24723 3/20 0.35
PRKCQ Q04759 3/20 0.35
ROCK2 O75116 2/20 0.35
ROCK1 Q13464 2/20 0.35
PKN1 Q16512 2/20 0.35
PKN2 Q16513 2/20 0.35
LATS1 O95835 2/20 0.35
PRKCA P17252 2/20 0.35
PRKCE Q02156 2/20 0.35
PRKCD Q05655 2/20 0.35
PRKCB P05771 1/20 0.35
LATS2 Q9NRM7 1/20 0.35
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9278638 0.82 ALDH1A1 (0.54) ALDH1A1FDPSHPGDNUDT1HRH4
SCHEMBL12385900 0.77 ALDH1A1 (0.48) ALDH1A1FDPSHPGDLMNAHTT
SCHEMBL6702893 0.76 CXCR4 (0.52) ALDH1A1FDPSHPGD
SCHEMBL17700115 0.73 ALDH1A1 (0.54) ALDH1A1FDPSHPGDIDH1
SCHEMBL3810001 0.72 PRKCH (0.43) ALDH1A1FDPSHPGDPRKCHPRKCQ
SCHEMBL3808178 0.71 POLB (0.45) ALDH1A1HPGDPRKCHPRKCQROCK2
SCHEMBL15471030 0.70 ALDH1A1 (0.62) ALDH1A1FDPSHPGDLMNAHTT
SCHEMBL17700463 0.70 ALDH1A1 (0.50) ALDH1A1FDPSHPGD
SCHEMBL6701443 0.69 ADORA2A (0.43) ALDH1A1HTT
SCHEMBL2488958 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3013827-A1 BROMODOMAIN INHIBITORS AbbVie Inc. (US) 2016-05-04 EP disclosed
WO-2014206345-A1 BROMODOMAIN INHIBITORS ABBVIE INC. (US) 2014-12-31 WO disclosed
US-20110201608-A1 SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-18 US disclosed
US-20110201608-A1 SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-18 US disclosed
US-20110201608-A1 SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-18 US disclosed
WO-2010015520-A1 SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-02-11 WO disclosed
US-20040180925-A1 Dipeptidylpeptidase-IV inhibitor KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-09-16 US disclosed
EP-1354882-A1 DIPEPTIDYL PEPTIDASE IV INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201608-A1 SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES NR4A1, NR4A3, NR0B1 ALDH1A1 1585/4885FDPS 3393/4885HPGD 2347/4885
US-20040180925-A1 Dipeptidylpeptidase-IV inhibitor DPP4, DPP3, DPP9 ALDH1A1 925/4885FDPS 2036/4885HPGD 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.